ADVOCATE Trial Now Enrolling

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
Participate in research:  ChemoCentryx has an ongoing Phase 3 clinical research study in ANCA-associated vasculitis (AAV) that is currently enrolling patients with AAV at various study locations across the United States. The study is called ADVOCATE.  Click here to learn more.